Treatment for Benzodiazepine Abuse

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Tolan Park Medical Building, Detroit, MI
Benzodiazepine Abuse+3 More
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

Opioid/Benzodiazepine Polydrug Abuse: Aim 3

See full description

Eligible Conditions

  • Benzodiazepine Abuse
  • Polysubstance Abuse
  • Opioid Abuse

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

This trial is evaluating whether Treatment will improve 3 primary outcomes and 16 secondary outcomes in patients with Benzodiazepine Abuse. Measurement will happen over the course of difference from placebo condition, measured within each session at 15-240 min post-drug 2 administration; measured in each of the 6 laboratory sessions over about 3 weeks.

Week 3
Sleep efficiency
Week 3
Cognitive flexibility performance task
Cognitive inhibition performance task
Hypothetical drug purchasing questionnaire
Impulsivity performance task accuracy
Monetary delay discounting questionnaire
Preference for natural reinforcement choice procedure
Symbol matching performance task
Vigilance performance task
Week 3
Blood pressure
Drug craving visual analog scale (VAS) ratings
Drug effect visual analog scale (VAS) ratings
Heart rate
Negative affect
Oxygen saturation
Positive affect
Pupil diameter
Respiration rate
Week 3
State anxiety

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

6 Treatment Groups

Morphine+alprazolam simultaneously
1 of 6
Alprazolam then morphine
1 of 6
Morphine alone
1 of 6
Alprazolam alone
1 of 6
Morphine then alprazolam
1 of 6
Placebo drug
1 of 6
Active Control
Non-Treatment Group

This trial requires 24 total participants across 6 different treatment groups

This trial involves 6 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.

Morphine+alprazolam simultaneouslymorphine 15mg + 0.25mg alprazolam at 9:30 am, then morphine 15mg + 0.25mg alprazolam at 12:00 pm
Alprazolam then morphine0.25mg oral alprazolam administered at 9:30 am, then 15mg oral morphine administered at 12:00 pm
Placebo drug
Drug
Lactose, administered both at 9:30 am and 12:00 pm
Morphine alone
Drug
15mg immediate-release oral morphine, administered both at 9:30 am and 12:00 pm
Alprazolam alone
Drug
0.25mg oral alprazolam, administered at both 9:30 am and 12:00 pm
Morphine then alprazolam15mg oral morphine administered at 9:30 am, then 0.25mg oral alprazolam administered at 12:00 pm

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: difference from placebo condition, measured on an outpatient basis during the evening after each laboratory drug administration; measured after each of the 6 laboratory sessions over about 3 weeks
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly difference from placebo condition, measured on an outpatient basis during the evening after each laboratory drug administration; measured after each of the 6 laboratory sessions over about 3 weeks for reporting.

Who is running the study

Principal Investigator
M. G.
Prof. Mark Greenwald, PhD
Wayne State University

Closest Location

Tolan Park Medical Building - Detroit, MI

Eligibility Criteria

This trial is for patients born any sex between 18 and 65 years old. There are 3 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
must self-report past 5-year experience taking opioid and sedative drugs (for therapeutic or non-therapeutic reasons), but not necessarily at the same time, and may have current mild- or moderate-severity Opioid Use Disorder or current mild- or moderate-severity Sedative Use Disorder;
must not be seeking treatment for their substance use problems;
must be in current good overall health

Patient Q&A Section

Ask a question about the study

Other questions from users

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any geographic restrictions to consider when applying for this trial?

Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.

Will my insurance cover participating in this trial?

In order to understand how insurance coverage works for this trial, you will need to contact the study coordinator.

See if you qualify for this trial
Get access to this novel treatment for Benzodiazepine Abuse by sharing your contact details with the study coordinator.